Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma
Author(s): Teeranachaideekul Veerawat, Boonsongsawat Worrawee, Asanawittaya Waralee, Jintapattanakit Anchalee, Chantasart Doungdaw, Wongrakpanich Amaraporn
Issue: Jan/Feb 2021 - Volume 25, Number 1
View All Articles in Issue
Page(s): 62-72
Download in electronic PDF format for $75
Abstract: Concentrated 7% w/w a-arbutin cream was formulated and evaluated using O/W and W/O emulsion bases as an extemporaneous preparation for melasma treatment. Cream bases were formulated with two pH values, 4.0 and 5.5, using a hot process. The stability of the creams was studied for 60 days under three storage conditions (i.e., 2°C to 8°C, 30°C, 40°C). Cream characteristics and all aspects of product stability including physical, chemical, and microbial were investigated. Stability was defined as no dramatic change in color, viscosity, pH, and no visible microbial growth. For stability, at least 90% of the initial a-arbutin concentration quantified by stability-indicating high-performance liquid chromatography must be obtained. It was found that pH had no influence on the a-arbutin or formulations’ stability. All formulations had a-arbutin remaining higher than 90% (approximately 92%) after being stored for 60 days in all storage conditions with no significant changes in pH or viscosity. All samples complied with the microbial limits test for nonsterile pharmaceutical preparation for cutaneous products. However, a color change was detected in O/W and W/O emulsions, especially at 40°C storage condition within 28 and 14 days, respectively. Drug crystals were observed in W/O emulsion stored at 2°C to 8°C. Concerning the in vitro drug release, a-arbutin was released from O/W emulsion but not from W/O emulsion. From the above results, the O/W emulsion that was developed in this study can be used as a cream base for concentrated a-arbutin as an extemporaneous preparation. The developed a-arbutin cream prepared using O/W emulsions can be used as an extemporaneous preparation with a beyond-use date of 60 days when stored at room temperature (30°C) and in the refrigerator (2°C to 8°C).
Related Keywords:
α-arbutin, alpha arbutin cream, hydroquinone derivative, tyrosinase inhibitor, melanin, topical preparations, melasma, skin pigment disorders, hyperpigmentation, physical stability, chemical stability, microbial growth
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma
Teeranachaideekul Veerawat, Boonsongsawat Worrawee, Asanawittaya Waralee, Jintapattanakit Anchalee, Chantasart Doungdaw, Wongrakpanich Amaraporn
|
Jan/Feb 2021
Pg. 62-72
|
Sensitization Therapy for Warts
Kuntz Rachael
|
Jul/Aug 2003
Pg. 266-270
|
Skin Disorders in Horses; Case Report: Tripelennamine in the Treatment of Skin Disorders in Horses
Williams LaVonn A, Fokken Dawn
|
Sep/Oct 2009
Pg. 386-389
|
Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
|
Jul/Aug 2004
Pg. 269-274
|
In Vitro Skin Penetration and Skin Content of Progesterone from Various Topical Formulations
Heustess Allie, Asbill Scott, Eagerton David, Arnold John
|
Nov/Dec 2014
Pg. 512-515
|
Evaluation of Percutaneous Absorption Performance for Human Female Sexual Steroids into Pentravan Cream
Polonini Hudson C, Brandão Marcos Antônio F, Ferreira Anderson O, Ramos Cristiano, Raposo Nádia R B
|
Jul/Aug 2014
Pg. 332-340
|
Deoxyarbutin 3% Anhydrous Emulsion
Allen Loyd V Jr
|
Jan/Feb 2022
Pg. 54
|
Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
|
Jul/Aug 2003
Pg. 288-291
|
Basics of Compounding for Dry-Skin Conditions
Allen Loyd V Jr
|
Nov/Dec 2003
Pg. 460-463
View Sample |
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Zur Eyal
|
Nov/Dec 2018
Pg. 446-454
|
NASEM Report on Compounded Topical Pain Creams
Allen Loyd V Jr
|
Nov/Dec 2020
Pg. 446-448
|
Nondetergent Neutral Dry Skin Cream
Allen Loyd V Jr
|
Sep/Oct 2007
Pg. 425
|
Physicochemical Stability of Compounded Creams Containing alpha-Hydroxy Acids
de Villiers Melgardt M, Narsai Kirti, van der Watt Jakkie G
|
Jan/Feb 2000
Pg. 72-75
|
Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
|
Sep/Oct 2015
Pg. 357-365
|
Sumatriptan, Lidocaine Hydrochloride, Dexamethasone, Pentoxifylline, and Ibuprofen Transdermal Cream (Migraine Cream)
Allen Loyd V Jr
|
Jul/Aug 2020
Pg. 320
|
Topical Oil-in-Water Cream Bases, Featured Excipient:
Allen Loyd V Jr
|
Jul/Aug 2002
Pg. 303-304
|
Compatibility of Estradiol, Estriol, Estrone, Progesterone, and Testosterone Single Formulation in Fitalite, Versatile, or HRT Supreme Cream Base
Polonini Hudson C, Dijkers Eli, Ferreira Anderson O, Zander Clark, Taylor Sarah
|
Jul/Aug 2021
Pg. 336-343
|
Aminophylline 3%, Co-dergocrine Mesylate 0.05%, and Isosorbide Dinitrate 0.25% Cream for the Treatment of Orgasmic Dysfunction in Women
Mason Dave
|
Jul/Aug 2002
Pg. 255-256
|
Breast Care Cream
Allen Loyd V Jr
|
Nov/Dec 2007
Pg. 505
|
Progesterone 10% Cream
Allen Loyd V Jr
|
Sep/Oct 2016
Pg. 412
|
Return to Top |